3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Recurrence
2
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Thyroid Diseases
1
Thoracic Neoplasms
1
Sarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Paraganglioma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Myelodysplastic Syndromes
1
Metastatic Urothelial Cancer
1
Lung Neoplasms
1
Lung Diseases
1
Low-grade Glioma
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Interventions
belzutifan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Has announcements
×
Paraganglioma
×
Clear all
NCT04924075
2026-05-11
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA